Farmitalia Carlo Erba

Carlo Erba

Farmitalia Certo Erba S.p.a.

Carmelo Gandolfi

Franco Faustini

Roberto Ceserani

Angelo Fumagalli

Carlo Passarotti

Maria M Usardi

Alessandro Andreoni

Renato Pellegata

Gianfederico Doria

Pietro Gaio

Nicola Mongelli

Enrico Di Salle

Vittoria Villa

Roberto Cesarani

Franco Fanstini

Allesandro Andreoni

Renato Pellegate

Walter Moretti

Mario M Usardi

William Fava

Omega furyl prostenynoic acids have been prepared.

13,14-Didehydro-prostaglandins and process for their preparation

Esters of 13,14-didehydro prostaglandins have been prepared.

Ester and amide derivatives of 13,14-didehydro prostaglandins

13, 14 didehydro-15 cyclic prostacyclins have been prepared.

15-Cycloaliphatic derivatives of 13,14-didehydro-carboprostacyclins and

Fluoro-prostaglandin compounds are disclosed, such as, for instance, 18,19,20-trinor-17-cyclohexyl-16(S,R)-fluoro-PGF.sub.2.alpha.. The fluoro-prostaglandins of the present invention have the same therapeutical uses as natural prostaglandins, but have the advantage of being resistant to the enzyme 15-prostaglandin dehydrogenase, and also exhibit a more selective therapeutical action. Certain of the compounds of the present invention exhibit very favorable luteolytic and antiulcer activity.

Fluoro-prostaglandins and process for their preparation

16-Fluoro-13,14-dehydro-PG.sub.2 series have been prepared, and their pharmaceutical use.

.omega.-Nor-cycloalkyl-13,14-dehydro-prostaglandin compounds, specifically 5c-9-oxo-11.alpha.,15S-dihydroxy-20,19,18-tirnor-17-cyclohexyl-prost-5-en- 13-ynoic acid, the esters and salts thereof, having antiulcer and luteolytic activity, are disclosed.

.omega.-Nor-cycloalkyl-13,14-dehydro-prostaglandins and process for

16-Fluoro-prostaglandins and pharmaceutical compositions containing the same are prepared. They are useful, for example, as anti-ulcer agents.

Cyclopenta[b]furan-2-one and -2-ol intermediates for

16-Fluro-13, 14-dehydro-PG.sub.2 series compounds have been prepared.

Fluoro-prostaglandins

2-oxa-bicyclic prostaglandins are provided, together with methods for their preparation and pharmaceutical and veterinary compositions containing same. The compounds have a wide range of pharmacological utilities, such as hypotensive agents, vasodilatory agents, and anti-aggregating agents.

Certain PGI.sub.1 compounds and their pharmaceutical composition and

15-Epi-Prostacyclin derivatives and compositions containing them having numerous pharmaceutical and veterinary utilities including, for example, anti-aggregating activity and anti-thrombolytic activity. Methods for preparing and using the compounds are also disclosed.

15-Epi-prostacyclin and analogous prostacyclins

Fluoro-prostaglandin compounds are disclosed, such as, for instance, 18,19,20-trinor-17-cyclohexyl-13-14-dehydro-16(S,R)-fluoro-PGF.sub.2.alpha .. The fluoro-prostaglandins of the present invention have the same therapeutical uses as natural prostaglandins, but have the advantage of being resistant to the enzyme 15-prostaglandin dehydrogenase, and also exhibit a more selective therapeutical action. Certain of the compounds of the present invention exhibit very favorable luteolytic and antiulcer activity.

9-deoxy-9A-methylene-isosteres of PGI.sub.2, including processes for their preparation and pharmaceutical and veterinary compositions containing same, are disclosed. The compounds are useful as therapeutic agents, for example as anti-aggregating agents, disaggregating agents, and as vasodilators.

9-Deoxy-9A-methylene isosteres of PGI.sub.2 and process for their

Bicyclic prostaglandins and pharmaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities, including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Bicyclic prostaglandins and process for their preparation

Bicyclic prostaglandins and pharamaceutical and veterinary compositions containing them having numerous pharmaceutical or veterinary utilities, including, for example, hypotensive, vasodilatory, anti-aggregating, luteolytic, and cytoprotective activities. Processes for preparing the compounds and compositions are also disclosed.

Pharmaceutically useful 5,6-saturated PGI compounds

Novel optically active 13,14-dehydro-11-deoxy-prostaglandins having a phenyl or substituted-phenyl group on the lower side chain are disclosed.

Growing community of inventors

Milan, Italy

Carmelo Gandolfi